SCHEMBL9909106

SCHEMBL9909106

CC1=C(C#N)[C@@H](C)C(C#N)=C(c2cccnc2)N1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.47
MAPT P10636 3/20 0.47
HTT P42858 3/20 0.47
NPC1 O15118 1/20 0.47
KMT2A Q03164 1/20 0.47
ALDH1A1 P00352 5/20 0.45
GAA P10253 4/20 0.45
GLA P06280 3/20 0.45
HPGD P15428 3/20 0.45
HSD17B10 Q99714 2/20 0.44
CASP1 P29466 1/20 0.44
CASP7 P55210 1/20 0.44
CYP11B2 P19099 1/20 0.42
NPSR1 Q6W5P4 2/20 0.40
CYP3A4 P08684 2/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
CACNA1C Q13936 1/20 0.38
CYP2A6 P11509 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9906923 0.85 KDM4E (0.43) KDM4EMAPTHTTNPC1KMT2A
SCHEMBL14155609 0.84 MAPT (0.46) KDM4EMAPTHTTNPC1KMT2A
SCHEMBL9909073 0.84 MAPT (0.46) KDM4EMAPTHTTNPC1KMT2A
SCHEMBL9909108 0.81 MAPT (0.44) KDM4EMAPTHTTNPC1KMT2A
SCHEMBL14155664 0.77 AR (0.38) KDM4EMAPTHTTNPC1KMT2A
SCHEMBL14155579 0.75 MET (0.38) KDM4EMAPTHTTNPC1KMT2A
SCHEMBL9909097 0.75 MET (0.38) KDM4EMAPTHTTNPC1KMT2A
SCHEMBL9909094 0.75 KDM4E (0.40) KDM4EMAPTKMT2AALDH1A1HPGD
SCHEMBL9909092 0.75 MET (0.53) KDM4EMAPTHTTKMT2AALDH1A1
SCHEMBL14155635 0.75 MET (0.42) KDM4EMAPTHTTNPC1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8198456-B2 e.g. 1,4-dihydro-4-(1H-indazol-5-yl)-2,6-dimethyl-3,5-pyridinedicarbonitrile; c-Met tyrosine kinase inhibitor; antitumor agent; lung, liver, gastric and breast solid tumors; pancreatic cancer, glioma, and hepatocellular carcinoma BAYER INTELLECTUAL PROPERTY GMBH (DE) 2012-06-12 US disclosed
US-20080176833-A1 DIHYDROPYRIDINE DERIVATIVES AS USEFUL AS PROTEIN KINASE INHIBITORS BAYER INTELLECTUAL PROPERTY GMBH (DE) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176833-A1 DIHYDROPYRIDINE DERIVATIVES AS USEFUL AS PROTEIN KINASE INHIBITORS MET, DMPK, RET KDM4E 1582/4885MAPT 1550/4885HTT 2390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.